Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 10/20 | 0.45 |
| ▸ | NPC1 | O15118 | 9/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.45 |
| ▸ | HPGD | P15428 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.39 |
| ▸ | RELA | Q04206 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27827661 | 0.81 | SIGMAR1 (0.38) | ALDH1A1RAB9AHPGDKDM4EMAPT | |
| Bromide SCHEMBL28711468 | 0.80 | SIGMAR1 (0.37) | ALDH1A1RAB9AHPGDKDM4EMAPT | |
| Hydrochloric Acid SCHEMBL27500541 | 0.80 | SIGMAR1 (0.37) | ALDH1A1RAB9AHPGDKDM4EKMT2A | |
| SCHEMBL18133049 | 0.77 | FAAH (0.38) | ALDH1A1POLBKCNH2TSHRKDM4E | |
| SCHEMBL9097301 | 0.75 | P2RX7 (0.41) | POLBKCNH2KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL28357122 | 0.74 | P2RX7 (0.40) | POLBKCNH2KDM4EMAPT | |
| Bromide SCHEMBL29152398 | 0.74 | P2RX7 (0.40) | POLBKCNH2KDM4EMAPT | |
| SCHEMBL31220302 | 0.73 | SRPK1 (0.36) | ALDH1A1KCNH2RAB9ANPC1KDM4E | |
| SCHEMBL28261453 | 0.69 | SIGMAR1 (0.49) | ALDH1A1RAB9ANPC1SMN1; SMN2HPGD | |
| SCHEMBL28790693 | 0.69 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2HPGDTSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153645-B2 | Use of analgesics to treat chronic pain using sodium channel modulators | ALLERGAN, INC. (US) | 2012-04-10 | — | — | US | claimed |
| US-8124612-B2 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | claimed |
| US-20060287366-A1 | TREATING PAIN USING SELECTIVE ANTAGONISTS OF PERSISTENT SODIUM CURRENT | EHRING GEORGE R | 2006-12-21 | — | — | US | claimed |
| EP-1658065-A2 | USING SELECTIVE ANTAGONISTS OF PERSISTENT SODIUM CURRENT TO TREAT NEUROLOGICAL DISORDERS AND PAIN | Allergan, Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050054695-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. | 2005-03-10 | — | — | US | claimed |
| WO-2005020982-A2 | USING SELECTIVE ANTAGONISTS OF PERSISTENT SODIUM CURRENT TO TREAT NEUROLOGICAL DISORDERS AND PAIN | ALLERGAN, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20050049287-A1 | Treating pain using selective antagonists of persistent sodium current | ALLERGAN, INC. | 2005-03-03 | — | — | US | claimed |
| US-9738710-B2 | Method of treating a patient for pain by administering an anti-ion channel antibody | UCB BIOPHARMA SPRL (BE) | 2017-08-22 | — | — | US | disclosed |
| US-9738710-B2 | Method of treating a patient for pain by administering an anti-ion channel antibody | UCB BIOPHARMA SPRL (BE) | 2017-08-22 | — | — | US | disclosed |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2016-08-04 | — | — | US | disclosed |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | UCB BIOPHARMA SPRL (BE) | 2016-08-04 | — | — | US | disclosed |
| US-9266953-B2 | Methods of treating pain using function modifying NAv1.7 antibodies | UCB BIOPHARMA SPRL (BE) | 2016-02-23 | — | — | US | disclosed |
| US-9266953-B2 | Methods of treating pain using function modifying NAv1.7 antibodies | UCB BIOPHARMA SPRL (BE) | 2016-02-23 | — | — | US | disclosed |
| US-7060723-B2 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| EP-1658065-A2 | USING SELECTIVE ANTAGONISTS OF PERSISTENT SODIUM CURRENT TO TREAT NEUROLOGICAL DISORDERS AND PAIN | Allergan, Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060106112-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20060106103-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050054695-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2005020982-A2 | USING SELECTIVE ANTAGONISTS OF PERSISTENT SODIUM CURRENT TO TREAT NEUROLOGICAL DISORDERS AND PAIN | ALLERGAN, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049287-A1 | Treating pain using selective antagonists of persistent sodium current | ALLERGAN, INC. | 2005-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049287-A1 | Treating pain using selective antagonists of persistent sodium current | KCNN3, KCNN2, SCN1B | ALDH1A1 1368/4885POLB 4446/4885KCNH2 59/4885 |
| US-20050054695-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | SCN1A, KCNN2, KCNN1 | ALDH1A1 1870/4885POLB 4599/4885KCNH2 57/4885 |
| US-20060106112-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | SCN1A, KCNN2, KCNN1 | ALDH1A1 1870/4885POLB 4599/4885KCNH2 57/4885 |
| US-20160222107-A1 | METHODS OF TREATING PAIN USING FUNCTION MODIFYING NAv1.7 ANTIBODIES | SCN7A, SCN3A, SCN1A | ALDH1A1 3169/4885POLB 3908/4885KCNH2 57/4885 |
| US-20060287366-A1 | TREATING PAIN USING SELECTIVE ANTAGONISTS OF PERSISTENT SODIUM CURRENT | KCNN3, KCNN2, SCN1B | ALDH1A1 1368/4885POLB 4446/4885KCNH2 59/4885 |
| US-20060106103-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | SCN1A, KCNN2, KCNN1 | ALDH1A1 1870/4885POLB 4599/4885KCNH2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.